Several toxicities are associated with molecular-targeted drugs including gastrointestinal adverse effects. These adverse effects need to be considered carefully because they can lead to the discontinuation of oral treatment and subsequently compromise cancer control. The authors of this Review discuss the incidence and clinical patterns of the gastrointestinal toxic effects induced by these agents and propose some hypotheses for each adverse event.
- Yohann Loriot
- Gabriel Perlemuter
- Jean-Charles Soria
